BOSTON, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) and certain of its officers and directors violated federal securities laws.
On February 11, 2019, Aurelius Value published an article titled, “Vanda: In the Land of The Blind, The One-Eyed Man is King.” According to this article, a 150-page whistleblower lawsuit contains detailed allegations that, “Vanda has engaged in a series of fraudulent schemes, some personally orchestrated by [its CEO], to defraud government payors.” The whistleblower lawsuit alleges “illegal off-label promotion of both of Vanda’s drugs, Vanda’s participation in a fraud involving doctors writing hundreds of ‘fake prescriptions’ and pocketing cash using Vanda-issued copay cards, falsified documents in internal systems, and resignations of senior executives who refused to participate in illegal activity.”
If you have purchased or otherwise acquired Vanda securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney Dan DeMaria at (888) 868-2385, by email at dan@blockesq.com, or by visiting http://shareholder.law/cases/?case=vanda.
Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
Dan DeMaria
(617) 398-5660 phone
155 Federal Street, Suite 400
Boston, MA 02110
dan@blockesq.com
SOURCE Block & Leviton LLP